Transaction · 0001213900-26-109132

Pham Quang X

Pham Quang X, CHAIR, reported a transaction classified as grant at Cadrenal Therapeutics, Inc. involving 200000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 200000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACHAIR
CVKDCadrenal Therapeutics, Inc.
Trade date
Oct 09, 2026
Filing date
Oct 13, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded200k$0.00 per share
Holdings after200kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

CVKD price since this filing

Daily closing prices, with the filing date and available return windows
CVKD · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +0.0%1w ago +0.0%1d ago +0.0%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001213900-26-109132
Stock Option
Transaction date
Oct 09, 2026
Filed Oct 13, 2026, 09:33 PM · 4d delay
Shares
200,000 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
200,000 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score

-10 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chairman and CEO

Officer YesDirector Yes10% YesOther No
Footnotes & amended
  1. F1

    The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise…

Original filing · 0001213900-26-109132
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

CVKD